These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25440437)

  • 1. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone.
    Draelos ZD
    J Am Acad Dermatol; 2015 Jan; 72(1):105-7. PubMed ID: 25440437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized and placebo-controlled study to compare the skin-lightening efficacy and safety of lignin peroxidase cream vs. 2% hydroquinone cream.
    Mauricio T; Karmon Y; Khaiat A
    J Cosmet Dermatol; 2011 Dec; 10(4):253-9. PubMed ID: 22151932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyspigmentation, skin physiology, and a novel approach to skin lightening.
    Draelos Z; Dahl A; Yatskayer M; Chen N; Krol Y; Oresajo C
    J Cosmet Dermatol; 2013 Dec; 12(4):247-53. PubMed ID: 24305422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation.
    Kolbe L; Mann T; Gerwat W; Batzer J; Ahlheit S; Scherner C; Wenck H; Stäb F
    J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():19-23. PubMed ID: 23205541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
    Serra M; Bohnert K; Narda M; Granger C; Sadick N
    J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effective hydroquinone alternative for topical skin lightening.
    Draelos ZD; Deliencourt-Godefroy G; Lopes L
    J Cosmet Dermatol; 2020 Dec; 19(12):3258-3261. PubMed ID: 33098161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Split-Face Comparison of an Advanced Non-Hydroquinone Lightening Solution to 4% Hydroquinone.
    Schlessinger J; Saxena S; Mohr S
    J Drugs Dermatol; 2016 Dec; 15(12):1571-1577. PubMed ID: 28095580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
    Fabi SG; Goldman MP
    J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
    Kaufman BP; Alexis AF
    J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone.
    Dahl A; Yatskayer M; Raab S; Oresajo C
    J Drugs Dermatol; 2013 Jan; 12(1):52-8. PubMed ID: 23377328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of hydroquinone-free skin-lightening cream for photoaging.
    Dreher F; Draelos ZD; Gold MH; Goldman MP; Fabi SG; Puissegur Lupo ML
    J Cosmet Dermatol; 2013 Mar; 12(1):12-7. PubMed ID: 23438137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening.
    Draelos ZD; Yatskayer M; Bhushan P; Pillai S; Oresajo C
    Cutis; 2010 Sep; 86(3):153-8. PubMed ID: 21049734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
    Bruce S
    J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.
    Makino ET; Mehta RC; Banga A; Jain P; Sigler ML; Sonti S
    J Drugs Dermatol; 2013 Mar; 12(3):s16-20. PubMed ID: 23545928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
    Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
    J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.
    Mendoza CG; Singzon IA; Handog EB
    Int J Dermatol; 2014 Nov; 53(11):1412-6. PubMed ID: 25265986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method for maintaining the clinical results of 4% hydroquinone and 0.025% tretinoin with a cosmeceutical formulation.
    Draelos ZD; Raab S; Yatskayer M; Chen N; Krol Y; Oresajo C
    J Drugs Dermatol; 2015 Apr; 14(4):386-90. PubMed ID: 25844613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentation.
    Wanner M; Houston N; Javorsky E; Yuan M; Alora-Palli M; Kimball AB
    J Drugs Dermatol; 2015 Jan; 14(1):13-8. PubMed ID: 25607903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of facial pigmentation of melasma by topical lignin peroxidase: A novel fast-acting skin-lightening agent.
    Zhong SM; Sun N; Liu HX; Niu YQ; Wu Y
    Exp Ther Med; 2015 Feb; 9(2):341-344. PubMed ID: 25574195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin lightening preparations and the hydroquinone controversy.
    Draelos ZD
    Dermatol Ther; 2007; 20(5):308-13. PubMed ID: 18045355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.